Retina Consultants Research at RCH Honolulu Hawaii

Clinical Trials Since 1993

Treatment options for wet-AMD and diabetic retinopathy are still being researched and studied.  Lucentis and Avastin have revolutionized the treatment of wet-AMD and Diabetic Retinopathy and prior to 2006, the medication was only available through clinical trials.  In Hawaii, these medications were available as early as 2002 through our research center (almost 4 years before it became FDA approved) through various clinical trials.  Sometimes, research trials can provide additional treatment options, research is not an option for everyone so please talk to us or your doctors if you feel that you might be a candidate for a clinical trial.  All research conducted at our clinic is reviewed by an Institutional Review Board as required by the FDA.

Below is a list of our currently enrolling trials:

  • HAWK-Evaluation of RTH258 in Patients with Treatment Naïve Wet-Age related Macular Degeneration (Primary Investigator:  Gregg T. Kokame, MD)
  • CHROMA- Evaluation of Lampalizumab in Patients with Geographic Atrophy secondary to Age-related Macular Degeneration (Primary Investigator: Gregg T. Kokame, MD)
  • ARGUS II Post Approval Study of the ARGUS II Retinal Prosthesis System (Primary Investigator:  Gregg T. Kokame, MD)
  • CEDAR- Evaluation of Abicipar Pegol in Patients with Treatment Naïve Wet Age-related Macular Degeneration (Primary Investigator:  James C. Lai, MD)
  • LHA 510- Topically delivered LHA510 for maintenance therapy of wet age-related macular degeneration (Primary Investigator: Raymond Wee, MD)
  • PALADIN- Safety assessment of IOP after treatment of Iluvien for DME (Primary Investigator: Gregg T. Kokame, MD)
  • OCT Angiography Study- Evaluation of Polypoidal Choroidal Vasculopathy with new OCT Angiography compared to FA and ICG imaging- Independent study-(Primary Investigator- Gregg T. Kokame, MD)

These studies have closed enrollment, but are still ongoing:

  • ORBIT- Ocriplasmin Research to Better Inform Treatment: Jetrea safety assessment for Vitreomacular Adhesion (Primary Investigator: Raymond Wee, MD)
  • EPIC- Study for Polypoidal Choroidal Vasculopathy- Independent Study – (Primary Investigator: Gregg T. Kokame, MD)
  • VAPOR-Evaluation of DE-120 in Patients with Treatment Naïve Wet Age-related Macular Degeneration (Primary Investigator: Gregg T. Kokame, MD)

These studies have been completed:

  • ACUCELA: Study for Dry Age-Related Macular Degeneration – (Primary Investigator: Gregg T. Kokame, MD)
  • PALM- Evaluation of Abicipar Pegol in Patients with Decreased Vision Due to Diabetic Macular Edema (Primary Investigator: Gregg T. Kokame, MD)
  • iDEAL Study for Diabetic Macular Edema- (Primary Investigator: Gregg T. Kokame, MD)
  • LPath – iSONEP -/+ Avastin, Eylea, or Lucentis for Exudative Age Related Macular Degeneration – (Primary Investigator: Gregg T. Kokame, MD)
  • CRAVE: Avastin vs Lucentis for Retinal Vein Occlusions – (Primary Investigator: Raymond Wee, MD)
  • PEARL2: 2.0mg Lucentis for PCV – (Primary Investigator: Gregg T. Kokame, MD)
  • VIEW 1: VEGF-Trap for wet-AMD (Primary Investigator: Gregg T. Kokame, MD)
  • VISTA: VEGF-Trap for Diabetic Macular Edema (Primary Investigator: Gregg T. Kokame, MD)
  • REACH Study for Wet-AMD – (Primary Investigator: Gregg T. Kokame, MD)
  • RISE Trial: ANTI-VEGF Therapy for the Treatment of Diabetic Retinopathy – Double-Masked, Randomized Study (Primary Investigator: Gregg T. Kokame, MD)
  • HARBOR: 2.0mg Lucentis for wet-AMD (Primary Investigator: Gregg T. Kokame, MD)
  • SHASTA: Retrospective Data Collection Study in Patients Receiving Two or More Ozurdex Impants – (Primary Investigator: James C. Lai, MD)
  • DIAMOND: rapamycin for Diabetic Macular Edema (Primary Investigator: Gregg T, Kokame, MD)
  • QUARK: siRNA for Wet-AMD – (Primary Investigator: Gregg T. Kokame, MD)
  • DRCR.net: OCT Comparison Study for Diabetic Macular Edema (Primary Investigator: Gregg T. Kokame)
  • PEARL Trial: Lucentis for Exudation and Bleeding related to Polypoidal Choroidal Vasculopathy (PCV) – (Primary Investigator: Gregg T. Kokame, MD)
  • siRNA for DME (Primary Investigator: Gregg T. Kokame, MD)
  • POSURDEX (Dexamethasone Sustained Release Pellet with Laser Photocoagulation for Diabetic Macular Edema – (Primary Investigator: James C. Lai, MD)
  • DRCR.net Evaluation of Vitrectomy for the Treatment of Diabetic Macular Edema – (Primary Investigator: Gregg T. Kokame, MD)
  • SAILOR: Lucentis for Choroidal Neovascularization Secondary to Wet-AMD (PI: Gregg T. Kokame, MD)
  • DRCR.net Intravitreal Steroid vs. Laser Photocoagulation for the Treatment of Diabetic Macular Edema – (PI: Gregg T. Kokame, MD)
  • DENALI Trial: Combination Therapy for Choroidal Neovascularization Secondary to Wet-AMD – (Primary Investigator: James C. Lai, MD)
  • MARINA: Lucentis for wet-AMD (Primary Investigator: Gregg T. Kokame, MD)
  • FOCUS: Lucentis + PDT for wet-AMD (Primary Investigator: Gregg T. Kokame, MD)
  • VISTa: Triamcinolone + PDT for wet-AMD (Primary Investigator: Gregg T. Kokame, MD)
  • EOP1012: Macugen + PDT for wet-AMD (Primary Investigator: Gregg T. Kokame, MD)
  • EOP1013: Macugen for Diabetic Macular Edema (Primary Investigator: Gregg T. Kokame, MD)
  • Prevention of Macular Hole Study (Primary Investigator: Gregg T. Kokame, MD)
  • Multi-center trial for the Prevention of Full-Thickness Macular Holes (Primary Investigator: Gregg T. Kokame, MD)
  • Vitrase for Vitreous Hemorrhage Study (Primary Investigator: Gregg T. Kokame, MD)
  • Protein Kinase C Inhibitor Study for Diabetic Retinopathy (Primary Investigator: Gregg T. Kokame, MD)
  • Submacular Surgery Trial (SST) for wet-AMD (Primary Investigator: Gregg T. Kokame, MD)
  • VAM Study: Visudyne for PDT (Co-Investigator: Gregg T. Kokame, MD)
  • STOP ROP Study (Retinopathy of Prematurity) (Co-Investigator: Gregg T. Kokame, MD)

If you are interested in participating in a clinical trial, please have your eye doctor or doctor contact Dr. Kokame,  Dr. Lai, or Dr. Wee to refer you to our office.  If you are interested in placing a study at Retina Consultants of Hawaii, please call our research department at at (808) 380-8060 or email: research@retinahi.com